Loading filters...
50 results(scroll for more)
HR+/HER2-Early Breast Cancer2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Gluz O et al. J Clin Oncol. 2026
HR+/HER2-Early Breast Cancer2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914).
Gluz O et al. Ann Oncol. 2026
HR+/HER2-both2026
An Analytical Framework Characterizes the Biological Processes that Shape Copy Number-Based Genome Instability Patterns in Breast Cancer.
Wong H et al. Cancer Res. 2026
HER2+ (HR-)both2026
TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial.
Wang S et al. ESMO Open. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Hurvitz SA et al. J Clin Oncol. 2026
HR+/HER2-Early Breast Cancer2026
Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.
van den Ende NS et al. NPJ Breast Cancer. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study.
Van Houdt M et al. ESMO Open. 2026
HR+/HER2-Early Breast Cancer2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.
Valenza C et al. J Clin Oncol. 2026
HER2+ (HR-)Advanced / Metastatic Breast Cancer2026
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.
Sánchez-Bayona R et al. ESMO Open. 2026
TNBCAdvanced / Metastatic Breast Cancer2026
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Dent R et al. Ann Oncol. 2026
HR+/HER2-Early Breast Cancer2026
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer.
Mayer EL et al. Ann Oncol. 2026
TNBCAdvanced / Metastatic Breast Cancer2026
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors.
Ruan DY et al. Ann Oncol. 2026
TNBCAdvanced / Metastatic Breast Cancer2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
Tolaney SM et al. N Engl J Med. 2026
HER2+ (HR-)Advanced / Metastatic Breast Cancer2026
Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.
Song PN et al. Breast Cancer Res Treat. 2026
HR+/HER2-both2026
TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression.
Wang DY et al. Br J Cancer. 2026
genomicAdvanced / Metastatic Breast Cancer2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.
Tung NM et al. J Clin Oncol. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.
Jacob S et al. ESMO Open. 2026
generalEarly Breast Cancer2026
Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy.
Tavares GM et al. Breast Cancer Res Treat. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.
Strawser CH et al. Clin Cancer Res. 2026
HR+/HER2-both2026
Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and older.
Stickland A et al. Breast Cancer Res Treat. 2026
TNBCEarly Breast Cancer2026
Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study.
Sterpi M et al. Breast Cancer Res Treat. 2026
HER2+ (HR-)Advanced / Metastatic Breast Cancer2026
Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study.
Stabellini N et al. Breast Cancer Res Treat. 2026
HR+/HER2-Early Breast Cancer2026
Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.
Soyano Muller AE et al. Breast Cancer Res Treat. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 Trial.
Juric D et al. Ann Oncol. 2026
HR+/HER2-Early Breast Cancer2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.
Francis PA et al. Ann Oncol. 2026
HR+/HER2-Early Breast Cancer2026
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial.
Penault-Llorca F et al. Eur J Cancer. 2026
HR+/HER2-both2026
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.
Robertson JFR et al. J Clin Oncol. 2026
TNBCboth2026
The SDC1-ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance.
Hou X et al. Cancer Res. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
Schmid P et al. Clin Cancer Res. 2026
TNBCAdvanced / Metastatic Breast Cancer2026
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.
Rugo HS et al. ESMO Open. 2026
HR+/HER2-both2026
Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.
Rubin SM et al. Cancer Res. 2026
generalEarly Breast Cancer2026
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
Chen X et al. J Clin Oncol. 2026
generalEarly Breast Cancer2026
Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?
Ravani LV et al. Breast Cancer Res Treat. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial.
Jhaveri K et al. Clin Cancer Res. 2026
HR+/HER2-Early Breast Cancer2026
Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.
Pagani O et al. Ann Oncol. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer.
Marchiò C et al. NPJ Breast Cancer. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.
Hörner M et al. Breast Cancer Res Treat. 2026
HR+/HER2-both2026
PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.
Dieci MV et al. Eur J Cancer. 2026
HR+/HER2-both2026
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Juric D et al. Clin Cancer Res. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.
Voorthuis RAB et al. Clin Cancer Res. 2026
HR+/HER2-Advanced / Metastatic Breast Cancer2026
Tucatinib Gives PFS Boost for Metastatic Breast Cancer.
Cancer Discov. 2026
HER2+ (HR-)both2026
Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.
Pougoue Ketchemen J et al. Br J Cancer. 2026
generalEarly Breast Cancer2026
Clinical Validation of Digital PCR-Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results.
Roseshter T et al. Clin Cancer Res. 2026
HR+/HER2+ (Triple Positive)Advanced / Metastatic Breast Cancer2026
PATINA — Palbociclib + Anti-HER2 Therapy + ET in HR+/HER2+ MBC
Metzger O et al. NEJM. 2026
genomicAdvanced / Metastatic Breast Cancer2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.
Hörner M et al. NPJ Breast Cancer. 2026
HR+/HER2-both2026
Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2mut breast tumors.
Wang L et al. NPJ Breast Cancer. 2026
generalboth2026
Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.
Park CS et al. JAMA Oncol. 2026
generalAdvanced / Metastatic Breast Cancer2026
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer.
Xu B et al. Ann Oncol. 2026
generalAdvanced / Metastatic Breast Cancer2026
OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
Rugo HS et al. Breast Cancer Res Treat. 2026
HR+/HER2-Early Breast Cancer2026
Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.
Nardin S et al. Eur J Cancer. 2026